Author

@TheStockerMan TheStockerMan

High-conviction long-only growth investor building AI-era valuation theses on a concentrated basket

Writes long-form fundamental and valuation theses on a conce

trader score
-0.21
hit rate
40%
mean α
-0.15%
signals 14d
183

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.

Their picks, scored

Across their last 20 scored bets: 40% hit rate, -0.15% mean alpha, trader score -0.21. Their last-14d mentions, direction-adjusted, have moved -4.0% since posting (mean over 157 mentions with price data).

Recent signals15receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-08-28NVDA@TheStockerMan+0.45Argues CRWV's valuation compressed while operating leverage, backlog, and AI-demand evidence improved.
2026-08-28CRWV@TheStockerMan+0.65Argues CRWV's valuation compressed while operating leverage, backlog, and AI-demand evidence improved.
2026-08-28DUOL@TheStockerMan+0.75Builds a long-term bullish framework for HIMS and DUOL despite near-term margin and bookings concerns.
2026-08-28HIMS@TheStockerMan+0.70Builds a long-term bullish framework for HIMS and DUOL despite near-term margin and bookings concerns.
2026-08-28NVO@TheStockerMan+0.30Argues HIMS's margin sacrifice funds customer growth, international expansion, and a broader health platform.
2026-08-28HIMS@TheStockerMan+0.75Argues HIMS's margin sacrifice funds customer growth, international expansion, and a broader health platform.
2026-08-28HIMS@TheStockerMan+0.70Expects short-term volatility but says the long-term HIMS thesis strengthened after earnings.
2026-08-28IREN@TheStockerMan-0.35Says expectations had moved ahead of IREN's actual infrastructure buildout.
2026-08-28IREN@TheStockerMan+0.05Warns against extrapolating one quarter and wants measurable improvement over coming quarters.
2026-08-28·@TheStockerMan·Criticizes an unidentified company for dilution, aggressive compensation, and unproven execution.·
2026-08-28NBIS@TheStockerMan+0.40Says NBIS has proven AI economics while IREN's potential margin advantage still needs evidence.
2026-08-28IREN@TheStockerMan+0.05Says NBIS has proven AI economics while IREN's potential margin advantage still needs evidence.
2026-08-28IREN@TheStockerMan-0.15Opportunity exists, but revenue conversion and execution remain key risks.
2026-08-28IREN@TheStockerMan-0.10Says IREN's outcome now depends entirely on execution.
2026-08-28NBIS@TheStockerMan+0.35Credits NBIS execution while saying IREN has not yet earned investor trust.

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.